First Tracks Shares Rise 15% Ahead of Celiac Trial Data Review
First Tracks Biotherapeutics said it would review top-line data from a celiac disease treatment trial on Monday. Shares rose 15% to $36.71 in premarket trading; they were up nearly 68% year to date through Friday's close.